A panelist discusses how managing biosimilars requires close collaboration between payers and health systems to optimize patient care and cost savings, while sharing insights about program ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption ...

Looking for information on Adrar Airport, Adrar, Algeria? Know about Adrar Airport in detail. Find out the location of Adrar Airport on Algeria map and also find out airports near to Adrar. This ...

The Global Oncology Biosimilars Market is expected to grow at 18.5% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...

and has been pivotal in advancing the company’s programs through establishing productive relationships and facilitating discussions with regulatory agencies regarding biosimilar development and ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...

Jeff Auletta, MD, discusses his key takeaways from the 2025 Transplant and Cellular Therapy Meetings. Jeff Auletta, MD, senior vice president of health equity at the National Marrow Donor Program and ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...

Bengaluru: BioconBiologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., has announced that YESINTEK (ustekinumab-kfce) is now available to patients in the United ...

Results from the phase 3 trial showed biosimilar denosumab was comparable to the reference product with regard to efficacy, safety, immunogenicity, PK, and pharmacodynamics (PD) in patients with ...